News

Lockdowns implemented for pandemic control have broad health, social, and economic consequences. This is especially true for people who live and work in slum communities around the world.

University of Maryland professor of medical technology answers where limited testing resources ought to be directed given pandemic supply issues.

Though it may be associated with the past in popular culture, tuberculosis is still the world’s most fatal infectious disease, killing an estimated 1.5 million people each year.

In a newly published paper, investigators believe the novel virus will follow similar patterns to seasonal viruses like influenza.

A new Danish study found no evidence of a causal association between the quadrivalent human papillomavirus vaccination and syndromes with autonomic dysfunction.

National Academies committee releases discussion draft on equitable allocation of vaccine against novel coronavirus for public comment.

New ACTT-2 findings show notable promise for a combination of the rheumatoid arthritis drug and the EUA-approved antiviral therapy.

Delayed or avoided medical care can increase death, severity of illness, and the chronic health impacts of acute illness.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

An examination of ventilator patients found a significant number of them could suffer from a variety of life-long injuries.

COVID-19 is a threat to everyone without immunity, but obese patients fare worse on average.

Review and meta-analysis identifies clinical manifestations, risk factors, and maternal and perinatal outcomes associated with COVID-19 in pregnancy.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Investigators resumed phase 3 international assessments after independent committees and regulators deemed it safe to do so.

In another of many hand sanitizer recalls since the start of the pandemic, FDA is working with Medek LLC to remove all lots of “M” hand sanitizer from store shelves.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

Robert H. Christenson, PhD, outlines the ways SARS-CoV-2 transmission is prevented during testing, how testing materials are acquired, and more.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

Results of the trial of Novavax’s NVX-CoV2373 vaccine have been published in the New England Journal of Medicine, showing the vaccine appeared safe and elicited strong immune responses.

Outbreaks in countries with high vaccine uptake prompted reassessment of the immunogenicity and persistence of trivalent measles, mumps and rubella vaccine

A new study in The Lancet maps trends in vaccine confidence around the world.

New guidance from the Infectious Diseases Society of America offers timely practice advice for the clinical treatment of three of the most common drug-resistant pathogens.

Decision Diagnostics Corp. has submitted 2 applications with the FDA for a COVID-19 testing technology that the firm claims can identify the virus in about 10 seconds.

New research presented at ERS shows how critically ill COVID-19 patients face cardiac and pulmonary burdens weeks after recovery.

The investigational vaccine was regarded as well-tolerated and elicited an immune response.

A new study that compared the results of a behavior intervention program for young adults living with HIV found outcomes were better when the intervention occurred in a clinic rather than at the patients’ homes.

A Rapid Response in BMJ argues that to achieve Zero-COVID, we need to broaden our thinking to include the controlled and careful acquisition of population immunity.